Atara Biotherapeutics (ATRA) Operating Leases (2019 - 2026)

Atara Biotherapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $9.1 million for Q1 2026.

• Quarterly Operating Leases fell 66.02% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (down 66.02% YoY) and the FY2025 annual result came in at $9.3 million, down 68.75% from the prior year.
• Operating Leases was $9.1 million for Q1 2026 at Atara Biotherapeutics, down from $9.3 million in the prior quarter.
• Across five years, Operating Leases topped out at $64.0 million in Q2 2022 and bottomed at $9.1 million in Q1 2026.
• A 5-year average of $36.7 million and a median of $38.7 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases soared 425.36% — and 2025, when it slumped 68.75%.
• Atara Biotherapeutics' Operating Leases stood at $58.1 million in 2022, then fell by 21.31% to $45.7 million in 2023, then slumped by 34.53% to $29.9 million in 2024, then slumped by 68.75% to $9.3 million in 2025, then slipped by 2.9% to $9.1 million in 2026.
• Business Quant data shows ATRA's Operating Leases at $9.1 million in Q1 2026, $9.3 million in Q4 2025, and $15.0 million in Q3 2025.